Overview

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: - Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine - Learn more about the side effects of ART0380 alone and in combination with gemcitabine - Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Artios Pharma Ltd
Treatments:
Gemcitabine